aTyr Pharma reports positive Phase 1b/2a results for ATYR1923; Q3 cash $116.4M

aTYR PHARMA INC

2022-Q3 EPS reported -$1.56

Positive proof-of-concept data for ATYR1923 in pulmonary sarcoidosis; registrational trial expected in 2022.
Cash, cash equivalents and investments $116.4M at Sept 30, 2021, after $80.6M net from stock offering.
R&D expenses $5.1M and G&A $2.6M for Q3 2021; 27.8M shares outstanding.
Appointed Robert W. Ashworth, PhD, as VP of Regulatory Affairs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.